Bionano Genomics, Inc. (BNGO) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BNGO Revenue Growth
Revenue Breakdown (FY 2025)
BNGO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
BNGO Revenue Analysis (2016–2025)
As of May 8, 2026, Bionano Genomics, Inc. (BNGO) generated trailing twelve-month (TTM) revenue of $28.5 million, reflecting slight decline in growth of -2.6% year-over-year. The most recent quarter (Q4 2025) recorded $8.0 million in revenue, up 7.9% sequentially.
Looking at the longer-term picture, BNGO's 5-year compound annual growth rate (CAGR) stands at +27.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $36.1 million in 2023.
Revenue diversification analysis shows BNGO's business is primarily driven by Product (48%), Consumable Revenue (25%), and Software Revenue (12%).
When compared to Healthcare sector peers including PACB (+3.9% YoY), CDNA (+19.2% YoY), and NTRA (+35.9% YoY), BNGO has underperformed the peer group in terms of revenue growth. Compare BNGO vs PACB →
BNGO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BNGOCurrent | $29M | -2.6% | +27.4% | -116.9% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% |
BNGO Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $28.5M | -7.4% | $14.1M | 49.4% | $-33,339,000 | -116.9% |
| 2024 | $30.8M | -14.8% | $380K | 1.2% | $-103,983,000 | -337.9% |
| 2023 | $36.1M | +29.9% | $9.6M | 26.5% | $-215,245,000 | -596.0% |
| 2022 | $27.8M | +54.6% | $5.9M | 21.4% | $-131,698,000 | -473.7% |
| 2021 | $18.0M | +111.5% | $3.9M | 21.5% | $-77,101,000 | -428.8% |
| 2020 | $8.5M | -16.1% | $2.8M | 32.6% | $-38,551,000 | -453.4% |
| 2019 | $10.1M | -15.6% | $3.4M | 33.2% | $-25,874,906 | -255.4% |
| 2018 | $12.0M | +26.3% | $3.3M | 27.4% | $-20,415,085 | -170.1% |
| 2017 | $9.5M | +39.9% | $3.5M | 36.6% | $-23,218,808 | -244.3% |
| 2016 | $6.8M | - | $3.2M | 47.3% | $-21,168,416 | -311.6% |
See BNGO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNGO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BNGO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBNGO — Frequently Asked Questions
Quick answers to the most common questions about buying BNGO stock.
Is BNGO's revenue growth accelerating or slowing?
BNGO revenue growth slowed to -2.6%, below the 5-year CAGR of +27.4%. TTM revenue is $29M. The deceleration marks a shift from historical growth rates.
What is BNGO's long-term revenue growth rate?
Bionano Genomics, Inc.'s 5-year revenue CAGR of +27.4% reflects the variable expansion pattern. Current YoY growth of -2.6% is near this long-term average.
How is BNGO's revenue distributed by segment?
BNGO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.